We use the latest gas-chromatography mass spectrometry (GC/MS) platform manufactured by Shimadzu, Japan, this is an extremely sensitive analysis platform that looks at the molecular level to identify the substances present in the urine.

After processing the urine specimen through GC/MS, we analyse the GC/MS data using a planar diagnostic tool, first developed by Japanese researchers. The planar diagnostic tool makes use of multiple analytes from more than one biochemical (metabolic) pathway to identify a single metabolic disorder. This means that the results would be far more reliable and accurate than traditional technology using mass tandem spectrometry (MS/MS) as MS/MS only uses about 1 or 2 analyte profiles for each disorder, and often, the same analyte profile is used for multiple disorders.